BioAlliance Pharma Receives €4.3 Million in Funding from bpifrance (ex OSEO) To Accelerate the Industrial Development of Livatag(R)

Regulatory News:

BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), a Company dedicated to the development of orphan oncology products and supportive care products, today announced funding of almost €9 million from bpifrance through a Strategic Industrial Innovation (ISI) program. An amount of €4.3 million will be allocated directly to BioAlliance Pharma to accelerate the industrial development of Livatag^®.

This grant supports the launch of NICE (Nano Innovation for Cancer), the first consortium of nanomedicine stakeholders in France focused on aspects of characterization and industrialization of processes specific to nanodrugs. The consortium has been accredited by the Medicen Paris Region, a competitive cluster for innovative therapies in Ile-de-France (www.medicen.org).

Consisting of five public and private partners and led by BioAlliance Pharma, the NICE consortium includes partners with deep expertise in the field of nanomedicine. Its mission is to build a platform to accelerate the development and industrialization of nanomedicine in France by capitalizing on the strong and complementary expertise of each partner.

Developed by BioAlliance Pharma, Livatag^®, a doxorubicin nanoparticle currently in phase III trial for the treatment of primary liver cancer, will fully benefit from this platform of expertise and the grant awarded by bpifrance will help accelerate the product’s development, especially in the industrial process.

In addition to BioAlliance Pharma, the consortium includes Nanobiotix, developer of NBTXR3, a potentiator of radiation therapy in the local treatment of cancer; CEA-Leti, developer of the Lipidots^® platform that uses lipid nanoparticles; DBI, a company specializing in the production of nanomedicine pharmaceutical products and Institut Galien Paris Sud (University Paris Sud/CNRS), which has an academic-excellence team specializing in nanoparticle research.

"The support and funding from bpifrance for our leader program Livatag^® is a key element to accelerate its industrial development in parallel with the ongoing phase III, thus reinforcing the value of this BioAlliance’s asset”, declared Judith Greciet, CEO of BioAlliance Pharma. "The launch of NICE consortium, including the best industrial and academic specialists in the nanotechnologies area, is an exciting project. We will share our experiences and expertise to build a French leadership and a European model of collaboration to accelerate the development and the market access of innovative nanomedicine meeting unsatisfied medical needs”.

About bpifrance’s Strategic Industrial Innovation (ISI) program
The Strategic Industrial Innovation program promotes the emergence of European champions. It supports ambitious, innovative collaborative projects through to industrialization, driven by innovative medium-sized companies (less than 5000 employees) and small businesses (less than 250 employees). These highly promising projects are aimed at the commercialization of products which result from technological breakthroughs and which not be possible without fostering measures from the public sector. Funding is generally in the €3-10 million range, as grants-in aid and loans which are repayable if the project is a success.

About BioAlliance Pharma
Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced product portfolio:

Specialty products
Loramyc^®/Oravig^® (oropharyngeal candidiasis in immunocompromised patients): Registered in 26 countries (EU, US, Korea), commercialized in Europe and in the US.
Sitavig^® (Acyclovir Lauriad^®) (labialis herpes): Registered in the US and in 8 European countries, registration status in the other European countries.
Fentanyl Lauriad^® (chronic cancer pain): Positive preliminary Phase I results

Orphan Oncology products
Livatag^® (Doxorubicin Transdrug™) (primary liver cancer): Phase III on going
Validive^® (Clonidine Lauriad^®) (mucositis): Phase II on going
AMEP^® (invasive melanoma): Phase I on going
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2012 Reference Document filed with the AMF on April 18, 2013, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).